Receptor-based 3D-QSAR in drug design: Methods and applications in kinase studies

Current Topics in Medicinal Chemistry

Volumn 16, Issue 13, 2016, Pages 1463-1477

  Fang, Cheng ^a   Xiao, Zhiyan ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Kinase inhibitors; Molecular alignments; Molecular descriptors; Receptor based 3D QSAR

Indexed keywords

CHOLINESTERASE INHIBITOR; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DIHYDROFOLATE REDUCTASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; INTERLEUKIN 2 INDUCIBLE T CELL KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PHOSPHOLIPASE A2; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; UROKINASE; LIGAND; PHOSPHOTRANSFERASE; PROTEIN KINASE INHIBITOR;

BINDING AFFINITY; CHEMICAL PROCEDURES; COMPARATIVE RESIDUE INTERACTION ANALYSIS; DNA SYNTHESIS; DRUG DESIGN; ENTHALPY; ENTROPY; MOLECULAR DOCKING; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; QUANTUM MECHANICS; REVIEW; SPHINGOMONAS PAUCIMOBILIS; THREE DIMENSIONAL QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP; XANTHOBACTER; ANTAGONISTS AND INHIBITORS; CHEMISTRY; HUMAN; METABOLISM; QUANTUM THEORY; SYNTHESIS;

DRUG DESIGN; HUMANS; LIGANDS; PHOSPHOTRANSFERASES; PROTEIN KINASE INHIBITORS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUANTUM THEORY;

EID: 84961744122     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150915120943     Document Type: Review

References (99)

1. Leach, A.R.; Shoichet, B.K.; Peishoff, C.E. Prediction of proteinligand interactions. Docking and scoring: successes and gaps. J. Med. Chem., 2006, 49(20), 5851-5855.
2. Huang, S.Y.; Zou, X. Advances and challenges in protein-ligand docking. Int. J. Mol. Sci., 2010, 11(8), 3016-3034.
3. Hansch, C.; Muir, R.M.; Fujita, T.; Maloney, P.P.; Geiger, F.; Streich, M. The correlation of biological activity of plant growth regulators and chloromycetin derivatives with Hammett constants and partition coefficients. J. Am. Chem. Soc., 1963, 85(18), 2817-2824.
4. Tropsha, A. In Burger's Medicinal Chemistry and Drug Discovery, 6th ed; Abraham, D.J., Ed.; John Wiley & Sons, Inc.: Chichester, 2003; Vol. 1, pp 49–76.
5. Cruciani, G.; Crivori, P.; Carrupt, P.A.; Testa, B. Molecular fields in quantitative structure–permeation relationships: the VolSurf approach. J. Mol. Struc., THEOCHEM, 2000, 503(1–2), 17-30.
6. Pastor, M.; Cruciani, G.; McLay, I.; Pickett, S.; Clementi, S. GRid- INdependent descriptors (GRIND): a novel class of alignmentindependent three-dimensional molecular descriptors. J. Med. Chem., 2000, 43(17), 3233-3243.
7. Tan, L.; Batista, J.; Bajorath, J., Computational methodologies for compound database searching that utilize experimental protein– ligand interaction information. Chem. Biol. Drug Des., 2010, 76(3), 191-200.
8. Sippl, W. In Recent Advances in QSAR Studies. Puzyn, T.; Leszczynski, J.; Cronin, M.T., Eds.; Springer Netherlands, 2010; Vol. 8, pp 103-125.
9. Cramer, R.D.; Patterson, D.E.; Bunce, J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc., 1988, 110(18), 5959-5967.
10. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem., 1994, 37(24), 4130-4146.
11. Bohm, H.J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J. Comput.-Aided Mol. Des., 1994, 8(3), 243-256.
12. Krystek, S.; Stouch, T.; Novotny, J. Affinity and specificity of serine endopeptidase-protein inhibitor interactions. Empirical free energy calculations based on X-ray crystallographic structures. J. Mol. Biol., 1993, 234(3), 661-679.
13. Head, R.D.; Smythe, M.L.; Oprea, T.I.; Waller, C.L.; Green, S.M.; Marshall, G.R. VALIDATE: A new method for the receptorbased prediction of binding affinities of novel ligands. J. Am. Chem. Soc., 1996, 118(16), 3959-3969.
14. Cornell, W.D.; Cieplak, P.; Bayly, C.I.; Gould, I.R.; Merz, K.M.; Ferguson, D.M.; Spellmeyer, D.C.; Fox, T.; Caldwell, J.W.; Kollman, P.A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc., 1995, 117(19), 5179-5197.
15. Di Santo, R.; Costi, R.; Artico, M.; Massa, S.; Ragno, R.; Marshall, G.R.; La Colla, P. Design, synthesis and QSAR studies on N-aryl heteroarylisopropanolamines, a new class of non-peptidic HIV-1 protease inhibitors. Bioorg. Med. Chem., 2002, 10(8), 2511-2526.
16. Ortiz, A.R.; Pisabarro, M.T.; Gago, F.; Wade, R.C. Prediction of drug binding affinities by comparative binding energy analysis. J. Med. Chem., 1995, 38(14), 2681-2691.
17. Wade, R.C.; Henrich, S.; Wang, T. Using 3D protein structures to derive 3D-QSARs. Drug Discov. Today. Technol., 2004, 1(3), 241-246.
18. Lushington, G.H.; Guo, J.X.; Wang, J.L. Whither combine? New opportunities for receptor-based QSAR. Curr. Med. Chem., 2007, 14(17), 1863-1877.
19. Perez, C.; Pastor, M.; Ortiz, A.R.; Gago, F. Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design. J. Med. Chem., 1998, 41(6), 836-852.
20. Tomic, S.; Nilsson, L.; Wade, R.C. Nuclear receptor-DNA binding specificity: A COMBINE and Free-Wilson QSAR analysis. J. Med. Chem., 2000, 43(9), 1780-1792.
21. Ortiz, A.R.; Pastor, M.; Palomer, A.; Cruciani, G.; Gago, F.; Wade, R.C. Reliability of comparative molecular field analysis models: effects of data scaling and variable selection using a set of human synovial fluid phospholipase A2 inhibitors. J. Med. Chem., 1997, 40(7), 1136-1148.
22. Vinkers, H.M.; de Jonge, M.R.; Daeyaert, E.D.; Heeres, J.; Koymans, L.M.; van Lenthe, J.H.; Lewi, P.J.; Timmerman, H.; Janssen, P.A. Inhibition and substrate recognition--a computational approach applied to HIV protease. J. Comput.-Aided Mol. Des., 2003, 17(9), 567-581.
23. Cuevas, C.; Pastor, M.; Perez, C.; Gago, F. Comparative binding energy (COMBINE) analysis of human neutrophil elastase inhibition by pyridone-containing trifluoromethylketones. Comb. Chem. High T. Scr., 2001, 4(8), 627-642.
24. Wang, T.; Wade, R.C. Comparative binding energy (COMBINE) analysis of OppA-peptide complexes to relate structure to binding thermodynamics. J. Med. Chem., 2002, 45(22), 4828-4837.
25. Lozano, J.J.; Pastor, M.; Cruciani, G.; Gaedt, K.; Centeno, N.B.; Gago, F.; Sanz, F. 3D-QSAR methods on the basis of ligandreceptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands. J. Comput.-Aided Mol. Des., 2000, 14(4), 341-353.
26. Kim, H.J.; Chae, C.H.; Yi, K.Y.; Park, K.L.; Yoo, S.E. Computational studies of COX-2 inhibitors: 3D-QSAR and docking. Bioorg. Med. Chem., 2004, 12(7), 1629-1641.
27. Martin-Santamaria, S.; Munoz-Muriedas, J.; Luque, F.J.; Gago, F. Modulation of binding strength in several classes of active site inhibitors of acetylcholinesterase studied by comparative binding energy analysis. J. Med. Chem., 2004, 47(18), 4471-4482.
28. Nakamura, S.; Nakanishi, I.; Kitaura, K. Binding affinity prediction of non-peptide inhibitors of HIV-1 protease using COMBINE model introduced from peptide inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(24), 6334-6337.
29. Murcia, M.; Morreale, A.; Ortiz, A.R. Comparative binding energy analysis considering multiple receptors: a step toward 3D-QSAR models for multiple targets. J. Med. Chem., 2006, 49(21), 6241-6253.
30. DeVore, N.M.; Smith, B.D.; Wang, J.L.; Lushington, G.H.; Scott, E.E. Key residues controlling binding of diverse ligands to human cytochrome P450 2A enzymes. Drug Metab. Dispos., 2009, 37(6), 1319-1327.
31. Wang, T.; Wade, R.C. Comparative binding energy (COMBINE) analysis of influenza neuraminidase-inhibitor complexes. J. Med. Chem., 2001, 44(6), 961-971.
32. Henrich, S.; Feierberg, I.; Wang, T.; Blomberg, N.; Wade, R.C. Comparative binding energy analysis for binding affinity and target selectivity prediction. Proteins, 2010, 78(1), 135-153.
33. Kmunicek, J.; Luengo, S.; Gago, F.; Ortiz, A.R.; Wade, R.C.; Damborsky, J. Comparative binding energy analysis of the substrate specificity of haloalkane dehalogenase from Xanthobacter autotrophicus GJ10. Biochemistry, 2001, 40(30), 8905-8917.
34. Kmunicek, J.; Bohac, M.; Luengo, S.; Gago, F.; Wade, R.C.; Damborsky, J. Comparative binding energy analysis of haloalkane dehalogenase substrates: modelling of enzyme-substrate complexes by molecular docking and quantum mechanical calculations. J. Comput.- Aided Mol. Des., 2003, 17(5-6), 299-311.
35. Kmunicek, J.; Hynkova, K.; Jedlicka, T.; Nagata, Y.; Negri, A.; Gago, F.; Wade, R.C.; Damborsky, J. Quantitative analysis of substrate specificity of haloalkane dehalogenase LinB from Sphingomonas paucimobilis UT26. Biochemistry, 2005, 44(9), 3390-3401.
36. Rodriguez-Barrios, F.; Gago, F. Chemometrical identification of mutations in HIV-1 reverse transcriptase conferring resistance or enhanced sensitivity to arylsulfonylbenzonitriles. J. Am. Chem. Soc., 2004, 126(9), 2718-2719.
37. Tomic, S.; Kojic-Prodic, B. A quantitative model for predicting enzyme enantioselectivity: application to Burkholderia cepacia lipase and 3-(aryloxy)-1,2-propanediol derivatives. J. Mol. Graph. Model., 2002, 21(3), 241-252.
38. Murcia, M.; Ortiz, A.R. Virtual screening with flexible docking and COMBINE-based models. Application to a series of factor Xa inhibitors. J. Med. Chem., 2004, 47(4), 805-820.
39. Gil-Redondo, R.; Klett, J.; Gago, F.; Morreale, A. gCOMBINE: A graphical user interface to perform structure-based comparative binding energy (COMBINE) analysis on a set of ligand-receptor complexes. Proteins, 2010, 78(1), 162-172.
40. Schleinkofer, K.; Wiedemann, U.; Otte, L.; Wang, T.; Krause, G.; Oschkinat, H.; Wade, R.C. Comparative structural and energetic analysis of WW domain-peptide interactions. J. Mol. Biol., 2004, 344(3), 865-881.
41. Wang, T.; Tomic, S.; Gabdoulline, R.R.; Wade, R.C. How optimal are the binding energetics of barnase and barstar? Biophys. J., 2004, 87(3), 1618-1630.
42. Tomic, S.W.; Wade, R.C. COMBINE analysis of nuclear receptor- DNA binding specificity: Comparison of two sets of data. Croat. Chem. Acta, 2001, 74(2), 295-314.
43. Tokarski, J.S.; Hopfinger, A.J. Prediction of ligand-receptor binding thermodynamics by free energy force field (FEFF) 3D-QSAR analysis: application to a set of peptidometic renin inhibitors. J. Chem. Inf. Comput. Sci., 1997, 37(4), 792-811.
44. Venkatarangan, P.; Hopfinger, A.J. Prediction of ligand-receptor binding thermodynamics by free energy force field threedimensional quantitative structure-activity relationship analysis: applications to a set of glucose analogue inhibitors of glycogen phosphorylase. J. Med. Chem., 1999, 42(12), 2169-2179.
45. Santos-Filho, O.A.; Mishra, R.K.; Hopfinger, A.J. Free energy force field (FEFF) 3D-QSAR analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors. J. Comput.-Aided Mol. Des., 2001, 15(9), 787-810.
46. Romeiro, N.C.; Albuquerque, M.G.; de Alencastro, R.B.; Ravi, M.; Hopfinger, A.J. Free-energy force-field three-dimensional quantitative structure-activity relationship analysis of a set of p38-mitogen activated protein kinase inhibitors. J. Mol. Model., 2006, 12(6), 855-868.
47. Gohlke, H.; Klebe, G. DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge- based pair-potentials to a particular protein. J. Med. Chem., 2002, 45(19), 4153-4170.
48. Gohlke, H.; Hendlich, M.; Klebe, G. Knowledge-based scoring function to predict protein-ligand interactions. J. Mol. Biol., 2000, 295(2), 337-356.
49. Silber, K.; Heidler, P.; Kurz, T.; Klebe, G. AFMoC enhances predictivity of 3D QSAR: a case study with DOXP-reductoisomerase. J. Med. Chem., 2005, 48(10), 3547-3563.
50. Datar, P.A.; Khedkar, S.A.; Malde, A.K.; Coutinho, E.C. Comparative residue interaction analysis (CoRIA): a 3D-QSAR approach to explore the binding contributions of active site residues with ligands. J. Comput.-Aided Mol. Des., 2006, 20(6), 343-360.
51. Khedkar, S.A.; Malde, A.K.; Coutinho, E.C. Design of inhibitors of the MurF enzyme of Streptococcus pneumoniae using docking, 3DQSAR, and de Novo design. J. Chem. Inf. Model., 2007, 47(5), 1839-1846.
52. Dhaked, D.K.; Verma, J.; Saran, A.; Coutinho, E.C. Exploring the binding of HIV-1 integrase inhibitors by comparative residue interaction analysis (CoRIA). J. Mol. Model., 2009, 15(3), 233-245.
53. Verma, J.; Khedkar, V.M.; Prabhu, A.S.; Khedkar, S.A.; Malde, A.K.; Coutinho, E.C. A comprehensive analysis of the thermodynamic events involved in ligand-receptor binding using CoRIA and its variants. J. Comput.-Aided Mol. Des., 2008, 22(2), 91-104.
54. Khedkar, V.M.; Joseph, J.; Pissurlenkar, R.; Saran, A.; Coutinho, E.C. How good are ensembles in improving QSAR models? The case with eCoRIA. J. Biomol. Struct. Dynamics, 2014, 1-21.
55. Vulpetti, A.; Crivori, P.; Cameron, A.; Bertrand, J.; Brasca, M.G.; D'Alessio, R.; Pevarello, P. Structure-based approaches to improve selectivity: CDK2-GSK3beta binding site analysis. J. Chem. Inf. Model., 2005, 45(5), 1282-1290.
56. Withers, I.M.; Mazanetz, M.P.; Wang, H.; Fischer, P.M.; Laughton, C.A. Active site pressurization: a new tool for structure-guided drug design and other studies of protein flexibility. J. Chem. Inf. Model., 2008, 48(7), 1448-1454.
57. Mazanetz, M.P.; Withers, I.M.; Laughton, C.A.; Fischer, P.M. A study of CDK2 inhibitors using a novel 3D-QSAR method exploiting receptor flexibility. QSAR Comb. Sci., 2009, 28(8), 878-884.
58. Kuhn, B.; Kollman, P.A. Binding of a diverse set of ligands to avidin and streptavidin: an accurate quantitative prediction of their relative affinities by a combination of molecular mechanics and continuum solvent models. J. Med. Chem., 2000, 43(20), 3786-3791.
59. Steinbrecher, T.; Case, D.A.; Labahn, A. A multistep approach to structure-based drug design: studying ligand binding at the human neutrophil elastase. J. Med. Chem., 2006, 49(6), 1837-1844.
60. Gallivan, J.P.; Dougherty, D.A. Cation-π interactions in structural biology. Proc. Natl. Acad. Sci. U.S.A., 1999, 96(17), 9459-9464.
61. Tsuzuki, S.; Honda, K.; Uchimaru, T.; Mikami, M.; Tanabe, K. Origin of the attraction and directionality of the NH/π interaction:_ Comparison with OH/π and CH/π interactions. J. Am. Chem. Soc., 2000, 122(46), 11450-11458.
62. Imai, Y.N.; Inoue, Y.; Nakanishi, I.; Kitaura, K. Cl–π interactions in protein–ligand complexes. QSAR Comb. Sci., 2009, 28(8), 869-873.
63. van der Vaart, A.; Merz, K.M. The role of polarization and charge transfer in the solvation of biomolecules. J. Am. Chem. Soc., 1999, 121(39), 9182-9190.
64. Raha, K.; Merz, K.M., Jr. Large-scale validation of a quantum mechanics based scoring function: predicting the binding affinity and the binding mode of a diverse set of protein-ligand complexes. J. Med. Chem., 2005, 48(14), 4558-4575.
65. Kitaura, K.; Ikeo, E.; Asada, T.; Nakano, T.; Uebayasi, M. Fragment molecular orbital method: an approximate computational method for large molecules. Chem. Phys. Lett., 1999, 313(3–4), 701-706.
66. Mazanetz, M.P.; Ichihara, O.; Law, R.J.; Whittaker, M. Prediction of cyclin-dependent kinase 2 inhibitor potency using the fragment molecular orbital method. J. Cheminform., 2011, 3(1), 2.
67. Zhang, X.; Gibbs, A.C.; Reynolds, C.H.; Peters, M.B.; Westerhoff, L.M. Quantum mechanical pairwise decomposition analysis of protein kinase B inhibitors: validating a new tool for guiding drug design. J. Chem. Inf. Model., 2010, 50(4), 651-661.
68. Pastor, M.; Perez, C.; Gago, F. Simulation of alternative binding modes in a structure-based QSAR study of HIV-1 protease inhibitors. J. Mol. Graph. Model., 1997, 15(6), 364-371, 389.
69. Pan, D.; Liu, J.; Senese, C.; Hopfinger, A.J.; Tseng, Y. Characterization of a ligand-receptor binding event using receptor-dependent four-dimensional quantitative structure-activity relationship analysis. J. Med. Chem., 2004, 47(12), 3075-3088.
70. Pan, D.; Tseng, Y.; Hopfinger, A.J. Quantitative structure-based design: formalism and application of receptor-dependent RD-4DQSAR analysis to a set of glucose analogue inhibitors of glycogen phosphorylase. J. Chem. Inf. Comput. Sci., 2003, 43(5), 1591-1607.
71. Dong, X.; Ebalunode, J.O.; Cho, S.J.; Zheng, W. A novel structurebased multimode QSAR method affords predictive models for phosphodiesterase inhibitors. J. Chem. Inf. Model., 2010, 50(2), 240-250.
72. Kearsley, S.K.; Smith, G.M. An alternative method for the alignment of molecular structures: Maximizing electrostatic and steric overlap. Tetrahedron Comput. Methodol., 1990, 3, (6, Part C), 615-633.
73. Reynolds, C.A.; Wade, R.C.; Goodford, P.J. Identifying targets for bioreductive agents: using GRID to predict selective binding regions of proteins. J. Mol. Graph., 1989, 7(2), 103-108, 100.
74. Cruciani, G.; Watson, K.A. Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b. J. Med. Chem., 1994, 37(16), 2589-2601.
75. Ciardiello, F.; Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med., 2008, 358(11), 1160-1174.
76. Citri, A.; Yarden, Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol., 2006, 7(7), 505-516.
77. Downward, J.; Parker, P.; Waterfield, M.D. Autophosphorylation sites on the epidermal growth factor receptor. Nature, 1984, 311(5985), 483-485.
78. Zhang, H.; Berezov, A.; Wang, Q.; Zhang, G.; Drebin, J.; Murali, R.; Greene, M.I. ErbB receptors: from oncogenes to targeted cancer therapies. J. Clin. Invest., 2007, 117(8), 2051-2058.
79. Kamath, S.; Buolamwini, J.K. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors. J. Med. Chem., 2003, 46(22), 4657-4668.
80. Jones, G.; Willett, P.; Glen, R.C.; Leach, A.R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol., 1997, 267(3), 727-748.
81. La Motta, C.; Sartini, S.; Tuccinardi, T.; Nerini, E.; Da Settimo, F.; Martinelli, A. Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structureactivity relationship analysis, and virtual screening studies. J. Med. Chem., 2009, 52(4), 964-975.
82. Wood, E.R.; Truesdale, A.T.; McDonald, O.B.; Yuan, D.; Hassell, A.; Dickerson, S.H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K.J.; Rusnak, D.W.; Gilmer, T.M.; Shewchuk, L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res., 2004, 64(18), 6652-6659.
83. Maybridge. http://www.maybridge.com.
84. Sun, X.Q.; Chen, L.; Li, Y.Z.; Li, W.H.; Liu, G.X.; Tu, Y.Q.; Tang, Y. Structure-based ensemble-QSAR model: a novel approach to the study of the EGFR tyrosine kinase and its inhibitors. Acta Pharmacol. Sin., 2014, 35(2), 301-310.
85. Nikolova, N.; Jaworska, J. Approaches to Measure Chemical Similarity – a Review. QSAR Comb. Sci., 2003, 22(9-10), 1006-1026.
86. Huang, N.; Shoichet, B.K.; Irwin, J.J. Benchmarking sets for molecular docking. J. Med. Chem., 2006, 49(23), 6789-6801.
87. Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K.; Shaw, D.E.; Francis, P.; Shenkin, P.S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem., 2004, 47(7), 1739-1749.
88. Siliciano, J.D.; Morrow, T.A.; Desiderio, S.V. itk, a T-cell-specific tyrosine kinase gene inducible by interleukin 2. Proc. Natl. Acad. Sci. U.S.A., 1992, 89(23), 11194-11198.
89. Ferrara, T.J.; Mueller, C.; Sahu, N.; Ben-Jebria, A.; August, A. Reduced airway hyperresponsiveness and tracheal responses during allergic asthma in mice lacking tyrosine kinase inducible T-cell kinase. J. Allergy Clin. Immunol., 2006, 117(4), 780-786.
90. von Bonin, A.; Rausch, A.; Mengel, A.; Hitchcock, M.; Kruger, M.; von Ahsen, O.; Merz, C.; Rose, L.; Stock, C.; Martin, S.F.; Leder, G.; Docke, W.D.; Asadullah, K.; Zugel, U. Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases. Exp. Dermatol., 2011, 20(1), 41-47.
91. Moriarty, K.J.; Winters, M.; Qiao, L.; Ryan, D.; DesJarlis, R.; Robinson, D.; Cook, B.N.; Kashem, M.A.; Kaplita, P.V.; Liu, L.H.; Farrell, T.M.; Khine, H.H.; King, J.; Pullen, S.S.; Roth, G.P.; Magolda, R.; Takahashi, H. Itk kinase inhibitors: initial efforts to improve the metabolical stability and the cell activity of the benzimidazole lead. Bioorg. Med. Chem. Lett., 2008, 18(20), 5537-5540.
92. Wang, J.; Li, F.; Li, Y.; Yang, Y.; Wang, B.; Zhang, S.; Yang, L. Insight into the structural requirements of benzimidazole derivatives as interleukin-2 inducible t-cell kinase inhibitors by computational explorations. Int. J. Quantum Chem., 2013, 113(21), 2385-2396.
93. Bahia, M.; Silakari, O. 3D-QSAR analysis of benzimidazole inhibitors of interleukin-2 inducible T cell kinase (ITK) considering receptor flexibility and water importance for molecular alignment. Med. Chem. Res., 2013, 22(11), 5578-5587.
94. Lo, H.Y.; Bentzien, J.; White, A.; Man, C.C.; Fleck, R.W.; Pullen, S.S.; Khine, H.H.; King, J.; Woska Jr, J.R.; Wolak, J.P.; Kashem, M.A.; Roth, G.P.; Takahashi, H. 2-Aminobenzimidazoles as potent ITK antagonists: de novo design of a pyrrole system targeting additional hydrogen bonding interaction. Tetrahedron Lett., 2008, 49(51), 7337-7340.
95. Shapiro, G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol., 2006, 24(11), 1770-1783.
96. Duca, J.S, Recent advances on structure-informed drug discovery of cyclin-dependent kinase-2 inhibitors. Future Med. Chem., 2009, 1(8), 1453-1466.
97. Chen, W.S.; Xu, P.-Z.; Gottlob, K.; Chen, M.-L.; Sokol, K.; Shiyanova, T.; Roninson, I.; Weng, W.; Suzuki, R.; Tobe, K.; Kadowaki, T.; Hay, N. Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 gene. Genes Dev., 2001, 15(17), 2203-2208.
98. Garofalo, R.S.; Orena, S.J.; Rafidi, K.; Torchia, A.J.; Stock, J.L.; Hildebrandt, A.L.; Coskran, T.; Black, S.C.; Brees, D.J.; Wicks, J.R.; McNeish, J.D.; Coleman, K.G. Severe diabetes, agedependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKBβ. J. Clin. Invest., 2003, 112(2), 197-208.
99. Zarubin, T.; Han, J. Activation and signaling of the p38 MAP kinase pathway. Cell Res., 2005, 15(1), 11-18.